A First-in-Pediatric Study of ALRN-6924, a Novel Stapled-Peptide Dual MDM2/MDMX Inhibitor, for Children with Advanced Hematologic and Solid Malignancies.

doi:10.1158/1078-0432.CCR-26-0625

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A First-in-Pediatric Study of ALRN-6924, a Novel Stapled-Peptide Dual MDM2/MDMX Inhibitor, for Children with Advanced Hematologic and Solid Malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research - 14 Aug 2026

Shulman David S, Vo Kieuhoa T, Balis Frank M, Lindsay Holly, DeNardo Bradley D, Place Andrew E, Chi Susan N, Kamihara Junne, O'Neill Allison F, Church Alanna J, Crompton Brian D, Klega Kelly, Tanhaemami Mohammad, Armant Myriam, Pikman Yana, Stegmaier Kimberly, Ezrre Suzanne, Czaplinski Jeffrey, Walensky Loren D, Annis D Allen, Bhushan Ketki, Kao Pei-Chi, London Wendy B, DuBois Steven G

Abstract excerpt

PURPOSE: ALRN-6924 is a stapled peptide that disrupts MDM2/MDMX-mediated inhibition of p53. We evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ALRN-6924 in children with advanced malignancies. PATIENTS AND METHODS: Patients with TP53 wild-type malignancies were enrolled in a monotherapy arm (solid/central nervous system tumors) or a combination arm with cytarabine (acute...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Cycle Proteins

Share to Circulating Tumor DNA

Share to Hematologic Neoplasms

Share to Peptides

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins c-mdm2

Share to Tumor Suppressor Protein p53

Source

Open in PubMed

Identifiers

PMID: 42189874
DOI: 10.1158/1078-0432.CCR-26-0625

Genes

TP53
MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A First-in-Pediatric Study of ALRN-6924, a Novel Stapled-Peptide Dual MDM2/MDMX Inhibitor, for Children with Advanced Hematologic and Solid Malignancies.PMID 42189874Read ↗

Clinical Overview of MDM2/X-Targeted TherapiesSemantic proximity Read ↗

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.Semantic proximity Read ↗

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task ForceSemantic proximity Read ↗

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancerSemantic proximity Read ↗

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.Semantic proximity Read ↗

Targeting the p53 pathway to treat Malignant Rhabdoid and Atypical Teratoid Rhabdoid TumorsSemantic proximity Read ↗

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.Semantic proximity Read ↗

Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma.Semantic proximity Read ↗

Baseline WT1-specific immunity and immune responses to WT1-targeted immunotherapy in pediatric patients with malignant solid tumors at high risk for relapse: results from a biomarker-driven multicenter translational phase II clinical trialSemantic proximity Read ↗

Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute LeukemiaSemantic proximity Read ↗

Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.Semantic proximity Read ↗

Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.